MBA 699 - Module 6 - Investor Pitch

5-1 Milestone Three: Alternative Buyer Research Report and Acquisition Road Map

MBA 699

Professor Shindell

September 24, 2022

5-1 Milestone Three: Alternative Buyer Research Report and Acquisition Road Map

The potential buyer selected for the organization is Vertex Pharmaceuticals. It is an American biopharmaceutical company based in Boston, Massachusetts. The company is known for its focus on innovation in research, manufacturing and distribution of medicines for severe illnesses. Vertex Pharmaceuticals was one of the first biofilm-producing medicines for life-threatening diseases and serious illnesses. Its customer's rate Vertex Pharmaceuticals up to 4.2 from 5 based on the services offered to customers. According to the organization's mission, Vertex Pharmaceuticals invests in scientific innovation to manufacture transformative medicine to deal with life-threatening and severe illnesses. Organizational values at Vertex Pharmaceuticals drive the operations and functions of the team. In this paper, we will discuss the current situation of Vertex Pharmaceuticals (Bakiny, 2022).

Current Market of Vertex Pharmaceuticals

The organization is operating in the pharmaceutical market in the United States. It holds a monopoly in the CF market. The company looks forward to working outside the CF market and diversifying its services through different locations. Based on the quality of research and manufacturing at Vertex Pharmaceuticals, it is expected that the organization will also gain enormous success in other regions. The uniqueness and differentiation that the organization has maintained would help it to compete across different locations and diversify its position in the international market (Bakiny, 2022).

Vertex Pharmaceuticals is the only firm manufacturing medicines to deal with healthcare complications. Some products manufactured by the company include TRIKAFTA/KAFTRIO, KALYDECO, SYMDEKO/SYMKEVI and ORKAMBI. These four medicines manufactured by Vertex are used to treat CF in the regions of Australia, North Africa and Europe. The company is also manufacturing other medicines to deal with chronic situations. Vertex Pharmaceuticals manufactures medicines by considering patient needs, and there is no compromise when it comes to a commitment to patients (Bakiny, 2022). Patients are central forces, and everything is for them what we do. Decisions from planning to manufacturing focus on patient need and ensure that organizational decisions should not impact customers.

All the patients suffering from severe life-threatening diseases are customers of Vertex Pharmaceuticals. The company is serving the medical needs of patients and using technology to manufacture transformative medicines for patients. The company invests in research, innovation and advancement to transform traditional medicine methods. All the company's decisions, programs and initiatives focus on patients and serving their needs directly or indirectly (VERTEX, 2009).

Vertex Pharmaceuticals is competing in the pharmaceuticals and biotherapeutics industry. It is serving the healthcare sector and innovating means of medicine. Some competitors of Vertex Pharmaceuticals include Biogen Mayokardia and Bellicum pharmaceuticals (Comparably, 2020). Vertex Pharmaceuticals is leading the market because of the innovation it drives in the healthcare sector and its distinct focus on health and medicine.

Financial Situations

According to the financial performance of the company in 2021, the product revenue of the company has increased compared to the previous year. Along with the overall success throughout the business, 22% revenue growth is recorded. According to the Chief Executive Officer and President of Vertex Pharmaceuticals, "we expanded our leadership in cystic fibrosis-- treating more patients than ever before and advancing our next-in-class triple regimen into pivotal studies. In addition, our pipeline beyond CF accelerated and delivered important clinical data in new disease areas" (VERTEX, 2022). She further states that moving in 2022, we have numerous other programs in mind that would help improve revenue growth even higher. We are motivated to serve many more patients, driving revenue growth and earnings in 2022 and years ahead (VERTEX, 2022). Financial highlights of the company during the second quarter of 2022 are as follows;

(VERTEX, 2022)

According to the chart above, the product revenue increased about 22%, $7.57 billion, compared to the previous year. The chart also shows that during 2022 cash flow and market securities increased by $9.3 billion compared to the previous year in 2021. The company's financial growth is dedicated to launching two products in the market, including KAFTRIO and TRIKAFTA. These two products have increased the operating income of Vertex and positively impacted the company's financial performance (VERTEX, 2022).

Recent Developments

Analysis of the recent developments in the company shows that the whole emphasis of Vertex Pharmaceuticals is on introducing new medicines to deal with chronic illnesses. Vertex Pharmaceuticals currently collaborates with Verve Therapeutics to discover and develop a gene editing program to address liver disease. According to the Chief Executive Officer at Vertex Pharmaceuticals, “This partnership with Vertex enables an important step forward for Verve as we build out our leading gene editing capabilities and pipeline of in vivo gene editing medicines to address serious diseases” (VERTEX, 2022). This initiative shows growing investments and efforts of the organization towards innovation and transformation of the healthcare sector.

Vertex Pharmaceuticals are also investing in improving technological advancement and embracing innovation in the workplace. The organization's purpose is to address chronic illnesses and improve the outlook of treatments for patients. The entire focus on innovation and advancement would improve patient and community care outcomes.

Buyer Rationale

Vertex Pharmaceuticals is the best option for a life sciences organization because the mission and purpose coincide. Vertex Pharmaceuticals focuses on cell, biology, and molecular level solutions, which is what the life sciences organization is doing; thus, collectively, both organizations can make a difference. Collaboration of Vertex Pharmaceuticals with life sciences organizations will help to manufacture products to treat chronic illnesses and would help to improve overall outcomes of healthcare for patients.

Acquisition Road Map

The organization for the acquisition is selected, and the next process is to negotiate business terms and conditions with each other. Both companies, Vertex Pharmaceuticals and the life sciences organization, will organize a meeting to discuss the agenda of the acquisition and share their expectations from each other. After the agenda setting, another meeting would be called to share common goals achieved through this acquisition. The roles and responsibilities of both companies will be communicated to eliminate complications later. Vertex Pharmaceuticals will explain its focus on research to drive innovation and how the organization could help it research and develop required changes in the contract. In the coming year, the manufacturing of new life-saving drugs will be discussed, along with changing market trends and patient needs. There would be different times and meetings to discuss all these things, and the road map would be implemented within two months to pursue decided goals in the coming year. Internal stakeholders from both organizations will participate in meetings and achieve acquisition goals. The roles and responsibilities of each stakeholder would be highlighted for them.

References

Bakiny, J. (2022, June 3). 2 Green Flags for Vertex Pharmaceuticals' Future. The Motley Fool. Retrieved September 25, 2022, from https://www.fool.com/investing/2022/06/03/2-green-flags-for-vertex-pharmaceuticals-future/

Comparably. (2020). Vertex Pharmaceuticals Competitors. Comparably. Retrieved September 25, 2022, from https://www.comparably.com/companies/vertex-pharmaceuticals/competitors

VERTEX. (2009, July 2). Home. YouTube. Retrieved September 25, 2022, from https://www.vrtx.com/patients/

VERTEX. (2022, January 26). Vertex Reports Second Quarter 2022 Financial Results. Vertex Pharmaceuticals. Retrieved September 25, 2022, from https://news.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2022-financial-results

VERTEX. (2022, July 20). Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom. Newsroom | Vertex Pharmaceuticals Newsroom. Retrieved September 25, 2022, from https://news.vrtx.com/news-releases/news-release-details/vertex-and-verve-therapeutics-establish-collaboration-discover-0